Metoprolol Tartrate* (Metoprolol Tartrate) — Medicare Part D spending
Multiple manufacturers (18) · Rank #307 by total Part D spend · CMS data year 2023
Medicare Part D spent $140,066,633 on Metoprolol Tartrate* (Metoprolol Tartrate) in 2023, the #307 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.0749 per dosage unit, $9 per claim and $36 per beneficiary, across 16,241,737 claims for 3,916,109 beneficiaries. Average spending per dosage unit rose +5.4% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Metoprolol Tartrate* (Metoprolol Tartrate) spending at a glance (2023)
| Metric | Metoprolol Tartrate* (Metoprolol Tartrate) |
|---|---|
| Total Part D spending (2023) | $140,066,633 |
| Total spending (2022) | $135,807,464 |
| Year-over-year change in total spending | +3.1% |
| Average spending per dosage unit (2023) | $0.0749 |
| Change in spend per dosage unit (YoY) | +5.4% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.2% |
| Average spending per claim (2023) | $9 |
| Average spending per beneficiary (2023) | $36 |
| Total claims (2023) | 16,241,737 |
| Beneficiaries (2023) | 3,916,109 |
| Total dosage units (2023) | 1,889,941,006 |
| Manufacturer(s) | Multiple manufacturers (18) |
| National rank by total spend (of 3,598 drugs) | #307 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $135,807,464 | $140,066,633 | +3.1% |
| Avg spend per dosage unit | $0.0711 | $0.0749 | +5.4% |
| Avg spend per claim | $8 | $9 | — |
| Avg spend per beneficiary | $34 | $36 | — |
| Total claims | 16,813,038 | 16,241,737 | — |
| Beneficiaries | 4,014,191 | 3,916,109 | — |
How Metoprolol Tartrate* compares with nearby drugs
Drugs with total Part D spending closest to Metoprolol Tartrate* (Metoprolol Tartrate):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Metoprolol Tartrate* (Metoprolol Tartrate) (this drug, #307) | $140,066,633 | $0.0749 | +5.4% |
| Movantik (Naloxegol Oxalate) (#305) | $140,596,853 | $13.91 | +3.0% |
| Lumakras (Sotorasib) (#306) | $140,234,716 | $111.46 | +34.9% |
| Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) (#308) | $140,028,972 | $25.57 | -7.2% |
| Avonex (Interferon Beta-1a) (#309) | $139,326,335 | $8,211.49 | +7.4% |
| Vyvanse (Lisdexamfetamine Dimesylate) (#310) | $138,990,768 | $13.04 | +5.8% |
Frequently asked questions
How much does Medicare Part D spend on Metoprolol Tartrate*?
Medicare Part D spent $140,066,633 on Metoprolol Tartrate* (Metoprolol Tartrate) in 2023 (the latest CMS data year), across 16,241,737 claims for 3,916,109 beneficiaries. That ranks #307 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Metoprolol Tartrate*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Metoprolol Tartrate* (Metoprolol Tartrate) was $0.0749. Compared with 2022 it rose +5.4%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Metoprolol Tartrate*?
CMS attributes Metoprolol Tartrate* (Metoprolol Tartrate) to Multiple manufacturers (18) in the 2023 Part D spending file. Average spending per claim was $9 and per beneficiary $36.
Is the Metoprolol Tartrate* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20